LIVIVO - Search results -

Search results

Result 1 - 10 of total 101

Search options

Article ; Online: Oncolytic adenoviruses and immunopeptidomics: a convenient marriage.

Garcia-Moure, Marc / Gillard, Andrew G / Alonso, Marta M / Fueyo, Juan / Gomez-Manzano, Candelaria

2024 Volume 18, Issue 4, Page(s) 781–784

Abstract: Oncolytic viruses (OVs) are biological therapeutic agents that selectively destroy cancer cells while sparing normal healthy cells. Besides direct oncolysis, OV infection induces a proinflammatory shift in the tumor microenvironment and the release of ... ...

Abstract	Oncolytic viruses (OVs) are biological therapeutic agents that selectively destroy cancer cells while sparing normal healthy cells. Besides direct oncolysis, OV infection induces a proinflammatory shift in the tumor microenvironment and the release of tumor-associated antigens (TAAs) that might induce an anti-tumor immunity. Due to their immunostimulatory effect, OVs have been explored for cancer vaccination against specific TAAs. However, this approach usually requires genetic modification of the virus and the production of a new viral vector for each target, which is difficult to implement for low prevalent antigens. In a recent study, Chiaro et al. presented an elegant proof of concept on how to implement the PeptiCRAd vaccination platform to overcome this limitation for the treatment of mesothelioma. Authors showed the feasibility of identifying immunogenic TAAs in human mesothelioma and using them to coat oncolytic adenovirus particles. The result was a customized virus-based cancer vaccine that circumvents time and resource-consuming steps incurred from genetically engineering viruses. Although some questions remain to be addressed, this interesting approach suggests novel strategies for personalized cancer medicine using oncolytic virotherapy.
MeSH term(s)	Humans ; Adenoviridae/genetics ; Marriage ; Oncolytic Viruses/genetics ; Oncolytic Virotherapy ; Neoplasms ; Mesothelioma/therapy ; Mesothelioma, Malignant ; Antigens, Neoplasm ; Tumor Microenvironment
Chemical Substances	Antigens, Neoplasm
Language	English
Publishing date	2024-04-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2415106-3
ISSN	1878-0261 ; 1574-7891
ISSN (online)	1878-0261
ISSN	1574-7891
DOI	10.1002/1878-0261.13648
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6637: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Targeting Innate Immunity in Glioma Therapy.

Gillard, Andrew G / Shin, Dong Ho / Hampton, Lethan A / Lopez-Rivas, Andres / Parthasarathy, Akhila / Fueyo, Juan / Gomez-Manzano, Candelaria

International journal of molecular sciences

2024 Volume 25, Issue 2

Abstract: Currently, there is a lack of effective therapies for the majority of glioblastomas (GBMs), the most common and malignant primary brain tumor. While immunotherapies have shown promise in treating various types of cancers, they have had limited success in ...

Abstract	Currently, there is a lack of effective therapies for the majority of glioblastomas (GBMs), the most common and malignant primary brain tumor. While immunotherapies have shown promise in treating various types of cancers, they have had limited success in improving the overall survival of GBM patients. Therefore, advancing GBM treatment requires a deeper understanding of the molecular and cellular mechanisms that cause resistance to immunotherapy. Further insights into the innate immune response are crucial for developing more potent treatments for brain tumors. Our review provides a brief overview of innate immunity. In addition, we provide a discussion of current therapies aimed at boosting the innate immunity in gliomas. These approaches encompass strategies to activate Toll-like receptors, induce stress responses, enhance the innate immune response, leverage interferon type-I therapy, therapeutic antibodies, immune checkpoint antibodies, natural killer (NK) cells, and oncolytic virotherapy, and manipulate the microbiome. Both preclinical and clinical studies indicate that a better understanding of the mechanisms governing the innate immune response in GBM could enhance immunotherapy and reinforce the effects of chemotherapy and radiotherapy. Consequently, a more comprehensive understanding of the innate immune response against cancer should lead to better prognoses and increased overall survival for GBM patients.
MeSH term(s)	Humans ; Glioma/therapy ; Immunotherapy ; Brain Neoplasms/therapy ; Glioblastoma/therapy ; Immunity, Innate
Language	English
Publishing date	2024-01-12
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms25020947
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas.

Meléndez-Vázquez, Natalie M / Nguyen, Teresa T / Fan, Xuejun / López-Rivas, Andrés R / Fueyo, Juan / Gomez-Manzano, Candelaria / Godoy-Vitorino, Filipa

Molecular therapy. Oncology

2024 Volume 32, Issue 1, Page(s) 200787

Abstract: Glioblastoma, the most common primary brain tumor, has a 6.8% survival rate 5 years post diagnosis. Our team developed an oncolytic adenovirus with an OX-40L expression cassette named Delta-24-RGDOX. While studies have revealed the interaction between ... ...

Abstract	Glioblastoma, the most common primary brain tumor, has a 6.8% survival rate 5 years post diagnosis. Our team developed an oncolytic adenovirus with an OX-40L expression cassette named Delta-24-RGDOX. While studies have revealed the interaction between the gut microbiota and immunotherapy agents, there are no studies linking the gut microbiota with viroimmunotherapy efficacy. We hypothesize that gut bacterial signatures will be associated with oncolytic viral therapy efficacy. To test this hypothesis, we evaluated the changes in gut microbiota in two mouse cohorts: (1) GSC-005 glioblastoma-bearing mice treated orally with indoximod, an immunotherapeutic agent, or with Delta-24-RGDOX by intratumoral injection and (2) a mouse cohort harboring GL261-5 tumors used to mechanistically evaluate the importance of CD4
Language	English
Publishing date	2024-02-28
Publishing country	United States
Document type	Journal Article
ISSN	2950-3299
ISSN	2950-3299
DOI	10.1016/j.omton.2024.200787
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Erratum: Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas.

Meléndez-Vázquez, Natalie M / Nguyen, Teresa T / Fan, Xuejun / López-Rivas, Andrés R / Fueyo, Juan / Gomez-Manzano, Candelaria / Godoy-Vitorino, Filipa

Molecular therapy. Oncology

2024 Volume 32, Issue 2, Page(s) 200801

Abstract: This corrects the article DOI: 10.1016/j.omton.2024.200787.]. ...

Abstract	[This corrects the article DOI: 10.1016/j.omton.2024.200787.].
Language	English
Publishing date	2024-04-17
Publishing country	United States
Document type	Published Erratum
ISSN	2950-3299
ISSN	2950-3299
DOI	10.1016/j.omton.2024.200801
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses.

Fueyo, Juan / Gomez-Manzano, Candelaria / Lang, Frederick F / Alonso, Marta M

The Lancet. Oncology

2021 Volume 22, Issue 8, Page(s) 1049–1051

MeSH term(s)	Brain Neoplasms/therapy ; Humans ; Oncolytic Virotherapy ; Oncolytic Viruses/genetics ; Stem Cells
Language	English
Publishing date	2021-06-29
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(21)00296-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Remission of liquid tumors and SARS-CoV-2 infection: A literature review.

Shin, Dong Ho / Gillard, Andrew / Van Wieren, Arie / Gomez-Manzano, Candelaria / Fueyo, Juan

Molecular therapy oncolytics

2022 Volume 26, Page(s) 135–140

Abstract: The coronavirus disease 2019 (COVID-19) pandemic has produced a new global challenge for patients with cancer. The disease and the immunosuppression induced by cancer therapies have generated a perfect storm of conditions to increase the severity of the ... ...

Abstract	The coronavirus disease 2019 (COVID-19) pandemic has produced a new global challenge for patients with cancer. The disease and the immunosuppression induced by cancer therapies have generated a perfect storm of conditions to increase the severity of the symptoms and worsen the prognosis. However, a few clinical reports showcased the power of viruses to induce remission in some patients suffering from liquid tumors. Here, we reviewed six cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that resulted in cancer remission, simultaneously highlighting the strengths and the unique challenges of oncolytic virotherapy. Virotherapy has become a special case of cancer immunotherapy. This paradigm-shifting concept suggests that oncolytic viruses are not only promising agents to combat particularly immunologically suppressed, immunotherapy-resistant tumors but also that the trigger of local inflammation, such as SARS-CoV-2 infection of the respiratory pathways, may trigger an abscopal effect sufficient to induce the remission of systemic cancer.
Language	English
Publishing date	2022-06-10
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2372-7705
ISSN	2372-7705
DOI	10.1016/j.omto.2022.06.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.

Vogelbaum, Michael A / Li, Gongbo / Heimberger, Amy B / Lang, Frederick F / Fueyo, Juan / Gomez-Manzano, Candelaria / Sanai, Nader

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

2022 Volume 42, Page(s) 1–8

Abstract: Glioblastoma is the most common primary malignant brain neoplasm and it remains one of the most difficult-to-treat human cancers despite decades of discovery and translational and clinical research. Many advances have been made in our understanding of ... ...

Abstract	Glioblastoma is the most common primary malignant brain neoplasm and it remains one of the most difficult-to-treat human cancers despite decades of discovery and translational and clinical research. Many advances have been made in our understanding of the genetics and epigenetics of gliomas in general; yet, there remains an urgent need to develop novel agents that will improve the survival of patients with this deadly disease. What sets glioblastoma apart from all other cancers is that it develops and spreads within an organ that renders tumor cells inaccessible to most systemically administered agents because of the presence of the blood-brain barrier. Inadequate drug penetration into the central nervous system is often cited as the most common cause of trial failure in neuro-oncology, and even so-called brain-penetrant therapeutics may not reach biologically relevant concentrations in tumor cells. Evaluation of the pharmacokinetics and pharmacodynamics of a novel therapy is a cornerstone of drug development, but few trials for glioma therapeutics have incorporated these basic elements in an organ-specific manner. Window-of-opportunity clinical trial designs can provide early insight into the biological plausibility of a novel therapeutic strategy in the clinical setting. A variety of window-of-opportunity trial designs, which take into account the limited access to treated tissue and the challenges with obtaining pretreatment control tissues, have been used for the initial development of traditional and targeted small-molecule drugs and biologic therapies, including immunotherapies and oncolytic viral therapies. Early-stage development of glioma therapeutics should include a window-of-opportunity component whenever feasible.
MeSH term(s)	Blood-Brain Barrier/pathology ; Brain Neoplasms/drug therapy ; Brain Neoplasms/pathology ; Glioblastoma/drug therapy ; Glioblastoma/pathology ; Glioma/drug therapy ; Humans ; Oncolytic Virotherapy
Language	English
Publishing date	2022-05-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	2431126-1
ISSN	1548-8756 ; 1548-8748
ISSN (online)	1548-8756
ISSN	1548-8748
DOI	10.1200/EDBK_349175
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Antitumor immune response during glioma virotherapy.

Youssef, Gilbert C / Gomez-Manzano, Candelaria / Sawaya, Raymond / Fueyo, Juan

Neuro-oncology

2019 Volume 21, Issue 9, Page(s) 1087–1088

MeSH term(s)	Brain Neoplasms/therapy ; Glioma/therapy ; Humans ; Oncolytic Virotherapy ; Pyridones ; Pyrimidinones
Chemical Substances	Pyridones ; Pyrimidinones ; trametinib (33E86K87QN)
Language	English
Publishing date	2019-07-26
Publishing country	England
Document type	Editorial ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S. ; Comment
ZDB-ID	2028601-6
ISSN	1523-5866 ; 1522-8517
ISSN (online)	1523-5866
ISSN	1522-8517
DOI	10.1093/neuonc/noz114
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5307: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.

Shin, Dong Ho / Jiang, Hong / Gillard, Andrew G / Kim, Debora / Fan, Xuejun / Singh, Sanjay K / Nguyen, Teresa T / Sohoni, Sagar S / Lopez-Rivas, Andres R / Parthasarathy, Akhila / Ene, Chibawanye I / Gumin, Joy / Lang, Frederick F / Alonso, Marta M / Gomez-Manzano, Candelaria / Fueyo, Juan

Molecular therapy : the journal of the American Society of Gene Therapy

2024 Volume 32, Issue 3, Page(s) 722–733

Abstract: Oncolytic viruses are a promising treatment for patients with high-grade gliomas, but neutralizing antibodies can limit their efficacy in patients with prior virus exposure or upon repeated virus injections. Data from a previous clinical trial using the ... ...

Abstract	Oncolytic viruses are a promising treatment for patients with high-grade gliomas, but neutralizing antibodies can limit their efficacy in patients with prior virus exposure or upon repeated virus injections. Data from a previous clinical trial using the oncolytic adenovirus Delta-24-RGD showed that generation of anti-viral neutralizing antibodies may affect the long-term survival of glioma patients. Past studies have examined the effects of neutralizing antibodies during systemic virus injections, but largely overlooked their impact during local virus injections into the brain. We found that immunoglobulins colocalized with viral proteins upon local oncolytic virotherapy of brain tumors, warranting a strategy to prevent virus neutralization and maximize oncolysis. Thus, we generated a chimeric virus, Delta-24-RGD-H43m, by replacing the capsid protein HVRs from the serotype 5-based Delta-24-RGD with those from the rare serotype 43. Delta-24-RGD-H43m evaded neutralizing anti-Ad5 antibodies and conferred a higher rate of long-term survival than Delta-24-RGD in glioma-bearing mice. Importantly, Delta-24-RGD-H43m activity was significantly more resistant to neutralizing antibodies present in sera of glioma patients treated with Delta-24-RGD during a phase 1 clinical trial. These findings provide a framework for a novel treatment of glioma patients that have developed immunity against Delta-24-RGD.
MeSH term(s)	Humans ; Animals ; Mice ; Adenoviridae/genetics ; Antibodies, Neutralizing ; Glioma/therapy ; Glioma/pathology ; Brain Neoplasms/pathology ; Oncolytic Viruses/genetics ; Oncolytic Virotherapy ; Antibodies, Viral ; Oligopeptides/therapeutic use
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; Oligopeptides
Language	English
Publishing date	2024-02-03
Publishing country	United States
Document type	Journal Article
ZDB-ID	2010592-7
ISSN	1525-0024 ; 1525-0016
ISSN (online)	1525-0024
ISSN	1525-0016
DOI	10.1016/j.ymthe.2024.01.035
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5640: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.

Jiang, Hong / Shin, Dong Ho / Yi, Yanhua / Fan, Xuejun / Gumin, Joy / He, Jiasen / Gillard, Andrew G / Lang, Frederick F / Gomez-Manzano, Candelaria / Fueyo, Juan

Cancer research communications

2023 Volume 3, Issue 6, Page(s) 1118–1131

Abstract: Cancer cell heterogeneity and immunosuppressive tumor microenvironment (TME) pose a challenge in treating solid tumors with adoptive cell therapies targeting limited tumor-associated antigens (TAA), such as chimeric antigen receptor T-cell therapy. We ... ...

Abstract	Cancer cell heterogeneity and immunosuppressive tumor microenvironment (TME) pose a challenge in treating solid tumors with adoptive cell therapies targeting limited tumor-associated antigens (TAA), such as chimeric antigen receptor T-cell therapy. We hypothesize that oncolytic adenovirus Delta-24-RGDOX activates the TME and promote antigen spread to potentiate the abscopal effect of adoptive TAA-targeting T cells in localized intratumoral treatment. Herein, we used C57BL/6 mouse models with disseminated tumors derived from B16 melanoma cell lines to assess therapeutic effects and antitumor immunity. gp100-specific pmel-1 or ovalbumin (OVA)-specific OT-I T cells were injected into the first subcutaneous tumor, followed by three injections of Delta-24-RGDOX. We found TAA-targeting T cells injected into one subcutaneous tumor showed tumor tropism. Delta-24-RGDOX sustained the systemic tumor regression mediated by the T cells, leading to improved survival rate. Further analysis revealed that, in mice with disseminated B16-OVA tumors, Delta-24-RGDOX increased CD8 Significance: Adjuvant therapy with oncolytic viruses promotes antigen spread to potentiate localized intratumoral adoptive T-cell therapy with limited TAA targets, leading to sustainable systemic antitumor immunity to overcome tumor relapse.
MeSH term(s)	Mice ; Animals ; Adenoviridae/genetics ; Cell Line, Tumor ; Mice, Inbred C57BL ; Neoplasm Recurrence, Local ; T-Lymphocytes, Cytotoxic ; Adenoviridae Infections ; Antigens, Neoplasm ; Tumor Microenvironment
Chemical Substances	Antigens, Neoplasm
Language	English
Publishing date	2023-06-27
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ISSN	2767-9764
ISSN (online)	2767-9764
DOI	10.1158/2767-9764.CRC-23-0054
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED